This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, G. G.
Right arrow Articles by Huband, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, G. G.
Right arrow Articles by Huband, M. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2663-2666, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01326-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Antibacterial Activity of CE-156811, a Novel Analog Derived from Hygromycin A{triangledown}

Gregory G. Stone,1* Dennis Girard,1 Steve Finegan,1 Joan Duignan,1 John Schafer,1 Meghan Maloney,1 Richard P. Zaniewski,1 Steven J. Brickner,1 Sarah K. Wade,1 Phuong T. Le,3 and Michael D. Huband2

Pfizer Global Research & Development, Groton/New London Laboratories, Pfizer Inc., Groton, Connecticut 06340,1 Pfizer Global Research & Development, Ann Arbor Laboratories, Pfizer Inc., Ann Arbor, Michigan 48105,2 Pfizer Global Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, California 921213

Received 15 October 2007/ Returned for modification 6 November 2007/ Accepted 9 April 2008

We evaluated a novel truncated hygromycin A analog in which the furanose ring was replaced with a 2-fluoro-2-cyclopropylethyl substituent for its activity against multidrug resistant gram-positive bacteria and compared its activity to the activities of linezolid, quinupristin-dalfopristin, and vancomycin. CE-156811 demonstrated robust in vitro activity against gram-positive bacteria that was comparable to that of linezolid.

* Corresponding author. Present address: Infection Biosciences, AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Waltham, MA 02451. Phone: (781) 839-4425. Fax: (781) 839-4800. E-mail: gregory.stone{at}astrazeneca.com

{triangledown} Published ahead of print on 21 April 2008.

Antimicrobial Agents and Chemotherapy, July 2008, p. 2663-2666, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01326-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»